OptimizeRx’s TelaRep™ Recognized as One of the Most Innovative Products for Life Sciences by PM360
11 Dezember 2020 - 1:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider
of digital health solutions for life science companies, physicians
and patients, announced its virtual communication solution,
TelaRepTM , has been recognized as one of the most innovative
products for life sciences by PM360 Magazine.
PM360, a leading publication for marketing decision makers in
the life sciences, recognizes the healthcare industry’s most
innovative companies, startups, divisions, products, services, and
strategies on its annual Innovation issue. The PM360 editorial
staff reviewed hundreds of submissions across all categories and
selected the top 16 innovative products for life sciences this
year.
“Innovation has been and will continue to be crucial as our
industry, and the world at large continues to deal with COVID-19
and the disruption and devastation it has caused,” said Anna
Stashower, CEO, publisher, and editor-in-chief of PM360. “The
innovative companies, offerings, and strategies found in this
year’s guide can provide the help that patients, healthcare
professionals, or life sciences organizations need during this time
as we all look toward making 2021 a healthier, safer, and overall
better new year.”
TelaRep provides a HIPAA-compliant, secure, virtual connection
that enables providers to easily contact the appropriate pharma
representative right from within the electronic health record.
Physicians can communicate directly with their pharma rep or
medical science liaisons (MSLs) and receive important support when
determining the best treatment regimen for a patient. The digital
solution fills the gap left by the absence of face-to-face
interactions between pharma reps and MSLs and providers in
today’s post-COVID world.
“Our team created TelaRep after we realized the pandemic would
begin to limit face-to-face communication between life sciences and
providers,” commented Steve Silvestro, chief commercial officer at
OptimizeRx. “We are honored to be recognized for a solution that
has an overall positive human impact.”
“TelaRep provides life science companies an efficient and
effective way to support providers who are treating patients with
complex disease states and especially where a gap in communication
could result in an adverse effect on their health,” continued
Silvestro. “We are excited to continue leveraging the power and
reach of our platform to innovate and deliver the best value to
life sciences, patients and providers.”
Earlier this year, PM360 Magazine recognized Silvestro with the
2020 PM360 ELITE 100 Award for his organizational leadership and
positive impact on the healthcare industry.
About OptimizeRx OptimizeRx is a
digital health company that provides communications solutions for
life science companies, physicians and patients. Connecting over
half of healthcare providers in the U.S. and millions of patients
through a proprietary network, the OptimizeRx digital
health platform helps patients afford and stay on medications. The
platform unlocks new patient and physician touchpoints for life
science companies along the patient journey, from point-of-care, to
retail pharmacy, through mobile patient engagement.
For more information, follow the company on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
Statements This press release contains
forward-looking statements within the definition of Section 27A of
the Securities Act of 1933, as amended, and such as in section 21E
of the Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially
from those set forth in, contemplated by, or underlying the
forward-looking statements. The risks and uncertainties to which
forward-looking statements are subject include, but are not limited
to, the effect of government regulation, competition and other
material risks.
OptimizeRx Contact Doug Baker,
CFO Tel (248) 651-6568
(x807) dbaker@optimizerx.com Media
Relations Contact Maira Alejandra, Media
Relations Manager Tel (754)
245-7070 malejandra@optimizerx.com Investor
Relations Contact Ron Both, CMA Tel (949)
432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024